Gerdtsson Anna S, Setayesh Sonia M, Malihi Paymaneh D, Ruiz Carmen, Carlsson Anders, Nevarez Rafael, Matsumoto Nicholas, Gerdtsson Erik, Zurita Amado, Logothetis Christopher, Corn Paul G, Aparicio Ana M, Hicks James, Kuhn Peter
USC Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA 90089, USA.
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel). 2021 Mar 2;13(5):1056. doi: 10.3390/cancers13051056.
Liquid biopsies hold potential as minimally invasive sources of tumor biomarkers for diagnosis, prognosis, therapy prediction or disease monitoring. We present an approach for parallel single-object identification of circulating tumor cells (CTCs) and tumor-derived large extracellular vesicles (LEVs) based on automated high-resolution immunofluorescence followed by downstream multiplexed protein profiling. Identification of LEVs >6 µm in size and CTC enumeration was highly correlated, with LEVs being 1.9 times as frequent as CTCs, and additional LEVs were identified in 73% of CTC-negative liquid biopsy samples from metastatic castrate resistant prostate cancer. Imaging mass cytometry (IMC) revealed that 49% of cytokeratin (CK)-positive LEVs and CTCs were EpCAM-negative, while frequently carrying prostate cancer tumor markers including AR, PSA, and PSMA. HSPD1 was shown to be a specific biomarker for tumor derived circulating cells and LEVs. CTCs and LEVs could be discriminated based on size, morphology, DNA load and protein score but not by protein signatures. Protein profiles were overall heterogeneous, and clusters could be identified across object classes. Parallel analysis of CTCs and LEVs confers increased sensitivity for liquid biopsies and expanded specificity with downstream characterization. Combined, it raises the possibility of a more comprehensive assessment of the disease state for precise diagnosis and monitoring.
液体活检作为肿瘤生物标志物的微创来源,在诊断、预后、治疗预测或疾病监测方面具有潜力。我们提出了一种基于自动化高分辨率免疫荧光,随后进行下游多重蛋白质分析的方法,用于并行单目标识别循环肿瘤细胞(CTC)和肿瘤衍生的大型细胞外囊泡(LEV)。大小>6 µm的LEV识别与CTC计数高度相关,LEV的出现频率是CTC的1.9倍,并且在73%的转移性去势抵抗性前列腺癌的CTC阴性液体活检样本中发现了额外的LEV。成像质谱流式细胞术(IMC)显示,49%的细胞角蛋白(CK)阳性LEV和CTC为EpCAM阴性,同时经常携带包括AR、PSA和PSMA在内的前列腺癌肿瘤标志物。HSPD1被证明是肿瘤衍生循环细胞和LEV的特异性生物标志物。CTC和LEV可以根据大小、形态、DNA含量和蛋白质评分进行区分,但不能通过蛋白质特征进行区分。蛋白质谱总体上是异质的,可以在不同对象类别中识别出聚类。对CTC和LEV的并行分析提高了液体活检的灵敏度,并通过下游表征扩展了特异性。综合起来,它增加了对疾病状态进行更全面评估以实现精确诊断和监测的可能性。